Skip to Main content Skip to Navigation
Journal articles

Pixantrone: a B-cell-depleting immunosuppressant for multiple sclerosis patients with active disease

Abstract : Background - Mitoxantrone has been approved for patients with worsening relapsing-remitting (RR) or secondary progressive multiple sclerosis (SPMS), but its long-term use is limited by its cardiotoxicity. Pixantrone (PIX) is an analog of mitoxantrone. Objectives - The aim of this open-label, multicenter, noncomparative Phase I/II trial was to explore the immunosuppressive effect of PIX, its impact on clinical disease activity and cerebral gadolinium-enhanced (Gd(+)) lesions, and its safety. Methods - Eighteen patients with active RRMS and SPMS (⩾ 1 cerebral Gd(+) lesion) despite approved immunomodulatory therapy received four intravenous PIX injections every 21 days. A neurological examination, hematology, lymphocyte subsets, and biochemistry were performed at Day 1, Weeks 3, 6 and 9, and Months 3, 6, 9 and 12. Echocardiography was performed before each infusion, at Months 3, 6 and 12. Cerebral MRI was performed at baseline, and at Months 6 and 12. Results - CD19+ cells were reduced by 95% at Month 3 and by 47% at Month 12. Gd+ lesions were reduced by 86% at Month 12 (p = 0.01). The annual relapse rate was reduced by 87% (p < 10(-4)). Two patients experienced a transient reduction in left ventricular fraction. Conclusion - These preliminary data indicate the efficacy of PIX in active RRMS and SPMS.
Document type :
Journal articles
Complete list of metadata
Contributor : Gilles Edan Connect in order to contact the contributor
Submitted on : Tuesday, January 28, 2020 - 11:34:37 AM
Last modification on : Saturday, June 25, 2022 - 9:17:15 AM



Richard Gonsette, Marc Debouverie, Christian Sindic, Jean-Christophe Ferré, Gilles Edan. Pixantrone: a B-cell-depleting immunosuppressant for multiple sclerosis patients with active disease. Multiple Sclerosis Journal, SAGE Publications, 2016, 22 (6), pp.817-821. ⟨10.1177/1352458515601902⟩. ⟨inserm-02457664⟩



Record views